Published in Pharma Investments, Ventures and Law Weekly, October 1st, 2006
According to recent research from Japan, "The hypotensive peptide adrenomedullin (AM) is assumed to act as a factor inhibitory on elevation of blood pressure and on progression of hypertensive organ damage, and plasma AM levels are elevated in patients with hypertension. The aim of the present study is to explore whether or not a rise in plasma AM levels precedes the development of hypertension."
J. Kato and colleagues at Miyazaki University in Kiyotake wrote, "Normotensive local...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly